RT Journal Article SR Electronic T1 Combinatorial effector targeting (COMET) for transcriptional modulation and locus-specific biochemistry JF bioRxiv FD Cold Spring Harbor Laboratory SP 2024.10.28.620517 DO 10.1101/2024.10.28.620517 A1 Wilson, Caroline M. A1 Pommier, Greg C. A1 Richman, Daniel D. A1 Sambold, Nicholas A1 Hussmann, Jeffrey A. A1 Weissman, Jonathan S. A1 Gilbert, Luke A. YR 2024 UL http://biorxiv.org/content/early/2024/10/28/2024.10.28.620517.abstract AB Understanding how human gene expression is coordinately regulated by functional units of proteins across the genome remains a major biological goal. Here, we present COMET, a high-throughput screening platform for combinatorial effector targeting for the identification of transcriptional modulators. We generate libraries of combinatorial dCas9-based fusion proteins, containing two to six effector domains, allowing us to systematically investigate more than 110,000 combinations of effector proteins at endogenous human loci for their influence on transcription. Importantly, we keep full proteins or domains intact, maintaining catalytic cores and surfaces for protein-protein interactions. We observe more than 5800 significant hits that modulate transcription, we demonstrate cell type specific transcriptional modulation, and we further investigate epistatic relationships between our effector combinations. We validate unexpected combinations as synergistic or buffering, emphasizing COMET as both a method for transcriptional effector discovery, and as a functional genomics tool for identifying novel domain interactions and directing locus-specific biochemistry.Competing Interest StatementC.M.W., G.C.P., J.S.W., and L.A.G. have filed patent applications on the platform/materials presented in this report. J.S.W. serves as an advisor to and/or has equity in 5 AM Ventures, Amgen, Chroma Medicine, KSQ Therapeutics, Maze Therapeutics, Tenaya Therapeutics and Tessera Therapeutics. L.A.G. has filed patents on CRISPR tools and CRISPR functional genomics, is a co-founder of Chroma Medicine, and a consultant for Chroma Medicine. The other authors declare no competing interests.